Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 11, Issue 11, Pages 2305-2311Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00423
Keywords
SIRT2; sirtuin inhibitor; PROTAC; cancer treatment; lysine defatty-acylase; lysine deacetylase
Categories
Funding
- NIH [R01DK107868]
Ask authors/readers for more resources
As a member of the sirtuin family of enzymes, SIRT2 promotes tumor growth and regulates various biological pathways through lysine deacetylation and defatty-acylation. In the past few years, many SIRT2-selective small molecule inhibitors have been developed, but none have demonstrated simultaneous inhibition of both SIRT2 activities in cells. To further scrutinize the physiological importance and significance of SIRT2 deacetylase and defatty-acylase activities, small molecules that can selectively inhibit both activities of SIRT2 in living cells are needed. Here, we have applied the Proteolysis Targeting Chimera (PROTAC) strategy and synthesized a new SIRT2 inhibitor (TM-P4-Thal) to degrade SIRT2 selectively, which led to simultaneous inhibition of its deacetylase and defatty-acylase activities in living cells. Additionally, this compound exemplifies the advantage of the PROTAC strategy that allows complete eradication of an enzyme and its activity in biological settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available